Brief: Sanofi's Wayrilz Approved In Japan For Immune Thrombocytopenia
23/06/2026 06:16
BRIEF-Sanofi's Wayrilz Approved In Japan For Immune Thrombocytopenia June 23 (Reuters) - Sanofi SA SASY.PA:
WAYRILZ APPROVED IN JAPAN TO TREAT IMMUNE THROMBOCYTOPENIA
APPROVAL IS BASED ON LUNA 3 PHASE 3 STUDY
Source text: ID:nGNX25J76W
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle